

Alimta (pemetrexed)

PROGRAM RATIONALE

Client Requested: The intent of the criteria is to ensure that patients follow selection elements established by Clover Health for Alimta.

CRITERIA FOR APPROVAL

1. Will the requested agent be used for non-small cell lung cancer with squamous histology?
 Yes
 No →
2. What is the patient's diagnosis?
 - a. Bladder cancer
 - b. Malignant pleural mesothelioma
 - c. Non-small cell lung cancer (non- squamous histology)
 - d. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer
 - e. Primary central nervous system lymphoma
 - f. Thymomas and thymic carcinomas
 - g. Malignant peritoneal mesothelioma
 - h. Pericardial mesothelioma
 - i. Tunica vaginalis testis mesothelioma
 - j. Cervical cancer
 - k. Other
3. Is the patient currently receiving therapy with the requested medication?
 Yes
 No

Continuation criteria

4. Is the patient receiving benefit from therapy with the requested medication as defined as no evidence of unacceptable toxicity and no evidence of disease progression while on the current regimen?
 Yes
 No

Initiation criteria

10. What is the patient's diagnosis?
 - a. Bladder cancer
 - b. Malignant pleural mesothelioma
 - c. Non-small cell lung cancer (non- squamous histology)
 - d. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer
 - e. Primary central nervous system lymphoma
 - f. Thymomas and thymic carcinomas
 - g. Malignant peritoneal mesothelioma
 - h. Pericardial mesothelioma
 - i. Tunica vaginalis testis mesothelioma

Reference number(s)
C22915-A

- i. ☐ Cervical cancer
- j. ☐ Other

Bladder cancer

11. Is the disease locally advanced, metastatic, or relapsed transitional cell urothelium cancer?
- Yes
 - No
12. Is the requested agent for second-line treatment?
- Yes
 - No

Malignant Pleural Mesothelioma

20. Will Alimta be used as a single agent or in combination with cisplatin or carboplatin?
- a. Yes, as a single agent
 - b. Yes, in combination with cisplatin or carboplatin
 - c. None of the above
21. Will Alimta be used in combination with bevacizumab and either cisplatin or carboplatin?
- a. Yes, in combination with bevacizumab and cisplatin
 - b. Yes, in combination with bevacizumab and carboplatin
 - c. None of the above

Ovarian cancer, fallopian tube cancer, and primary peritoneal cancer

30. Will Alimta be used for treatment of any of the following?
- a. Epithelial cancer
 - b. Fallopian tube cancer
 - c. Primary peritoneal cancer
 - d. Carcinosarcoma (malignant mixed Mullerian tumors)
 - e. Clear cell carcinoma
 - f. Grade 1 endometrioid carcinoma
 - g. Low-grade serous carcinoma/ovarian borderline epithelial tumor (low malignant potential) with invasive implants
 - h. Mucinous carcinoma
 - i. Other
31. Is the disease persistent or recurrent?
- Yes
 - No
32. Will Alima be used as a single agent?
- Yes
 - No

Primary central nervous system lymphoma

40. Will Alima be used as a single agent?

Yes

No

Thymomas and thymic carcinomas

50. Will Alimta be used as a single agent?

Yes

No

Cervical cancer

60. Is the disease persistent or recurrent?

Yes

No

I. SUMMARY OF EVIDENCE

1. Alimta [package insert]. Indianapolis, IN. Lilly USA, LLC; February 2021.

II. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.